
    
      Product: Kineret (anakinra) Comparative agents: Methotrexate or azathioprine or leflunomide
      or cyclosporin A or sulphasalazine Protocol title: An open, randomized study treating
      refractory adult-onset Still's disease with IL-1ra anakinra (Kineret, compared to an
      established, single anti-rheumatic treatment Target Disease: Adult-onset Still's disease
      Patients: 23 patients diagnosed with AOSD, living in the four Nordic countries.

      Study Objectives: To follow the changes in clinical status and disease activity in patients
      receiving anakinra, compared to those treated with an established DMARD, in addition to
      corticosteroids in patients with refractory AOSD. To compare the changes in disease-related
      parameters (global health, patient's assessment on disease, laboratory values) in the two
      randomized groups. To assess the safety of anakinra in AOSD. To follow-up drug survival,
      efficacy, tolerability and disease-related parameters of long-term treatment in AOSD (open
      phase).
    
  